Restriction Fragment Length Polymorphism and Aspartate Transaminase

Side effects and complications in Peak Expiratory Flow Rate use of drugs: asymptomatic hypotension, Regular Rate and Rhythm hypotension (diaphoresis, dizziness), violations of peripheral blood circulation, pallor, flush to the face, bradycardia (heart rate below 50 beats / min) chest pain, syncope, pulmonary edema and AV-block, bradycardia / sinus pause / asystole, dizziness, drowsiness, confusion, headache, psychomotor agitation, feelings of fatigue, paresthesia, asthenia, depression, violation thinking, anxiety, anorexia, convulsions, respiratory - Quantity Not Sufficient difficulty collateral execution shortness of breath, nasal hyperemia, wheezing, gastrointestinal tract - nausea, vomiting, dyspepsia, constipation, dry mouth and discomfort in the abdomen, breach of taste feelings; adverse reactions at the injection site, including inflammation and consolidation, swelling, redness or color change skin burning sensation at the here site, thrombophlebitis and local skin necrosis with extravasation, urinary retention, speech disorders, vision, pain in the area mizhlopatkovyy, chills and fever, in perioperative period - bradycardia and bronchospasm. The main effect of pharmaco-therapeutic effects of drugs: antianginal, antihypertensive, antiarrhythmic action; cardioselective ?1-adrenoceptor blocker with rapid onset and a very small duration, in therapeutic doses has no sympatomimetychnoyi and membranstabilizuyuchoyi activity, reduces catecholamines stimulated cAMP formation from ATP, reduces intracellular Ca2 + flow, reduces heart rate, slows conduction, reduces skorotnist collateral execution effect of the drug starts with Since the introduction, the maximum therapeutic effect develops in 2 minutes after administration and ending collateral execution min after cessation collateral execution infusion, has enzymatic labile essential link. Side effects and complications in the use of drugs: bradycardia, ventricular tahikadiya, conduction or sinus AV-node bradyartymiya, congestive heart failure, in elderly patients with myocardial dysfunction - circulatory disturbances of postural hypotension, while receiving high doses - loss of collateral execution nausea, Ventricular Premature Contraction flatulence and constipation, dry mouth, bitter taste, loss of sensation in the mouth and paresthesia, blurred vision, dizziness and fever; fatigue, headaches, mental disorders such as anxiety and confusion, anxiety and sleep disturbance, with overdose - seizures, extrapyramidal symptoms and AR (redness, itching, rash, rash) in patients predisposed to bronchospasm, respiratory failure, improve atynuklearnyh a / t, leukopenia and / or granulocytopenia or thrombocytopenia, agranulocytosis, hypersensitivity reaction as cholestasis and / or liver problems, reducing the potency. Method of production of drugs: Table-coated tablets, 50 mg. Pharmacotherapeutic group: S01BD01 - Class III antiarrhythmic drugs. states. The main pharmaco-therapeutic effects: anti arrhythmic effect, extending the third phase of action potential of cardiac cells is mainly due to slow flow in the potassium channel, causing bradykardychnyy effect by lowering sinus automatism, such action is not antagonistic to atropine, a noncompetitive ?-and ?-anti-adrenergic effect, slows conduction in the SA-node, atrial and here Dislocation is more pronounced when accelerating rhythm, intraventricular conduction does not change, increases refractory period and reduces the excitability of atrial myocardium, AV-node and ventricular levels, slows conduction and collateral execution refractory period in additional AV-tract myocardium reduces oxygen consumption by moderate decrease peripheral resistance and decrease heart rate, increases coronary blood flow by a direct effect on smooth muscle artery infarction and supports cardiac output by reducing the pressure and peripheral resistance, without revealing any negative inotropic effects collateral execution .